RETA-MAX-12
Retatrutide|12 mg × 10 Vials
A research product containing retatrutide, an investigational triple hormone receptor agonist being studied in clinical research.
Each vial contains 12 mg, with 10 vials per kit, providing a total labeled quantity of 120 mg. Retatrutide is being investigated for its activity at the GIP, GLP-1, and glucagon receptors, with current clinical development including research in obesity, type 2 diabetes, and several obesity-related conditions.
Product Highlights
About Retatrutide
Retatrutide (LY3437943) is an investigational molecule being developed by Eli Lilly. It is a single molecule that activates three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
Because of this three-receptor activity, retatrutide is commonly described as a triple agonist.
Clinical research has investigated retatrutide in areas including obesity and overweight, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, cardiovascular and renal outcomes, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease.
Importantly, retatrutide remains investigational and has not been approved by the FDA. Lilly currently states that it is being evaluated in Phase 3 clinical trials.
RETA-MAX-12 is therefore presented as an investigational research compound for qualified laboratory applications, rather than as an approved therapeutic product.
Product Specifications
| PRODUCT NAME | RETA-MAX-12 |
| COMPOUND | Retatrutide |
| ALTERNATIVE IDENTIFIER | LY3437943 |
| QUANTITY PER VIAL | 12 mg |
| NUMBER OF VIALS | 10 |
| TOTAL QUANTITY | 120 mg |
| PRODUCT TYPE | Investigational Research Compound |
| MOLECULAR CLASSIFICATION | GIP / GLP-1 / Glucagon Triple Agonist |
| PHYSICAL FORM | Verify with manufacturer |
| INTENDED APPLICATION | Laboratory / Research Use |
| PACKAGING | 10-vial kit |
| BRAND | Maxtreme Pharma |
Note: The packaging confirms the 12 mg vial strength and 10-vial configuration. Physical form, purity, formulation, and other analytical specifications should be taken from the manufacturer's current technical documentation or CoA rather than inferred from the image.
Research Applications
Retatrutide is currently being investigated in clinical and scientific research because of its activity across the GIP, GLP-1, and glucagon receptor pathways. Research areas include:
Lilly's Phase 3 development program includes studies examining retatrutide across obesity and related metabolic conditions.
These research areas describe ongoing scientific and clinical investigation and should not be presented as approved medical indications for this product.
Retatrutide Research Profile
Retatrutide represents a multi-receptor approach to metabolic research, combining activity at the GIP, GLP-1, and glucagon receptors within a single molecule.
This mechanism has made retatrutide an area of significant clinical investigation, particularly in metabolic and cardiometabolic research.
Phase 3 studies have reported substantial effects on body weight and other metabolic measures in investigational settings. However, these clinical-trial results should be distinguished from regulatory approval and should not be used to imply that an independently supplied product has the same safety, quality, formulation, or clinical characteristics as the investigational material used in those trials.
Quality & Packaging
The RETA-MAX-12 kit contains 10 individually packaged vials, with 12 mg of labeled retatrutide per vial, providing a total labeled quantity of 120 mg per kit.
The product packaging identifies the compound as Retatrutide and specifies the individual vial strength and overall kit quantity.
For professional research procurement, researchers should verify the applicable:
- Certificate of Analysis (CoA)
- Batch / lot number
- Compound identity
- Purity specification
- Assay results
- Analytical testing
- Formulation information
- Storage requirements
For an investigational compound such as retatrutide, batch-specific analytical documentation is particularly important.
Storage & Handling
Store and handle RETA-MAX-12 according to the manufacturer's batch-specific technical documentation and Certificate of Analysis.
The stability of peptide-based or biologically active research materials can depend on factors including temperature, moisture, light exposure, formulation, and handling conditions.
Researchers should follow the manufacturer's documented storage and handling requirements rather than relying on generic storage recommendations.
Appropriate laboratory procedures and applicable safety protocols should be followed when handling experimental research materials.
RETA-MAX-12 contains retatrutide, an investigational compound.
Retatrutide is not currently approved by the FDA and remains under clinical investigation.
This product should not be represented as an approved medication or as a treatment for obesity, diabetes, weight loss, or any other medical condition.
This product is intended only for qualified research and laboratory applications, subject to applicable laws, regulations, institutional requirements, and laboratory safety procedures.
No claim is made that this specific product is safe or effective for the diagnosis, treatment, cure, or prevention of any disease or medical condition.
Not for human consumption or self-administration.
Frequently Asked Questions
RETA-MAX-12 is a research product containing retatrutide, an investigational molecule that activates the GIP, GLP-1, and glucagon receptors.
Each vial contains 12 mg according to the product packaging.
The kit contains 10 vials.
The kit contains 120 mg total, calculated as: 10 vials × 12 mg = 120 mg.
Retatrutide, also known as LY3437943, is an investigational triple hormone receptor agonist developed by Eli Lilly. It activates the GIP, GLP-1, and glucagon receptors.
Clinical research has investigated retatrutide in obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, cardiovascular and renal outcomes, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease, among other areas.
No. As of September 2026, retatrutide has not been approved by the FDA and remains an investigational compound in clinical development.
Not exactly. Calling retatrutide simply a “GLP-1” is inaccurate. Retatrutide is a triple receptor agonist that acts on GIP, GLP-1, and glucagon receptors.
No. The product should be presented as For Research Use Only and not for human consumption or self-administration.
Professional research customers should request the applicable Certificate of Analysis (CoA) and batch information, including identity, purity, assay, testing, and storage information.